

DAFTAR PUSTAKA

- Azizah, L., 2008. 'Terapi Hipertensi di Masa Depan', . *Majalah Kedokteran Indonesia*, Vol. 58–2;53–54.
- Brunton, L. dan Goodman, L.S., 2007. *Goodman and Gilman's Manual of Pharmacology and Therapeutics*. McGraw Hill Professional.
- Campbell, S., Moffatt, R.J., dan Stamford, B.A., 2008. Smoking and smoking cessation -- the relationship between cardiovascular disease and lipoprotein metabolism: a review. *Atherosclerosis*, **201**: 225–235.
- Cassar, A., Holmes, D.R., Rihal, C.S., dan Gersh, B.J., 2009. Chronic coronary artery disease: diagnosis and management. *Mayo Clinic Proceedings*, **84**: 1130–1146.
- Chapman, M.J., Redfern, J.S., McGovern, M.E., dan Giral, P., 2010. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacology & Therapeutics*, **126**: 314–345.
- Choi, S.-Y. dan Mintz, G.S., 2010. What have we learned about plaque rupture in acute coronary syndromes? *Current Cardiology Reports*, **12**: 338–343.
- Dahlan, 2013. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*, Edisi 3. ed. Salemba Medika.
- Dahlan, M., 2013. *Statistik Untuk Kedokteran Dan Kesehatan*, edisi 5. ed. Salemba Medika, Jakarta.
- Evans, J., 2012. Atherosclerosis and Heart Disease, dalam: *Crash Course Cardiovascular Disease*. Elseiver Ltd, London, hal. 85.
- Finks, S.W., 2007. Cardiovascular Disease in women. *PSAP-VII Cardiology*, 179–199.
- Forey, B.A., Fry, J.S., Lee, P.N., Thornton, A.J., dan Coombs, K.J., 2013. The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. *Biomarker Research*, **1**: 26.
- Gaisenok, O., Martsevich, S., Tripkosh, S., dan Lukina, Y., 2015. Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. *Revista Portuguesa de Cardiologia*, **34**: 111–116.
- Gepner, A.D., Piper, M.E., Johnson, H.M., Fiore, M.C., Baker, T.B., dan Stein, J.H., 2011. Effects of smoking and smoking cessation on lipids and

lipoproteins: outcomes from a randomized clinical trial. *American Heart Journal*, **161**: 145–151.

Gofir, A., 2012. *Manajemen Stroke Evidence Based Medicine*. Pustaka Cendekia Press, Yogyakarta.

Greene, R.J. dan Harris, H.D., 2008. *Pathology and Therapeutics For Pharmacists: A Basic for Clinical Pharmacy Practice*, 3 th. ed. Cambridge University Press.

Grundy, S.M., Cleeman, J.I., Merz, C.N.B., Brewer, H.B., Clark, L.T., Hunnigake, D.B., dkk., 2004. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation*, **110**: 227–239.

Hulten, E., Jackson, J.L., Douglas, K., George, S., dan Villines, T.C., 2006. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. *Archives of Internal Medicine*, **166**: 1814–1821.

Irawan, 2006. How Coronary Artery Disease (CAD) Develop to Acute Coronary Syndrome (ACS), dalam: *Cardiovaskular Disease: From Circulation to Metabolic Problem, Naskah Lengkap 2 Nd Jogja Cardiology*. Bagian Kardiologi dan Kedokteran vaskular Fakultas Kedokteran UGM, Yogyakarta.

Jones, P.H., Nair, R., dan Thakker, K.M., 2012. Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis. *Journal of the American Heart Association*, **1**: e001800.

Kabo, P., 2008. *Penyakit Jantung Koroner*. Gramedia Pustaka Utama, Jakarta.

Kadoglou, N., Sailer Nikolaos, Moutzouoglou Anestis, Kapelouzou Alkistis, Geramidis, T., dan Liapis, C.D., 2010. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. *Journal of Vascular Surgery*, **51**: 114–21.

Karalis, D.G., Victor, B., Ahedor, L., Liu, L., Karalis, D.G., Victor, B., dkk., 2012. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients, Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. *Cholesterol, Cholesterol*, **2012, 2012**: e861924.

- Katsiki, N., Papadopoulou, S.K., Fachantidou, A.I., dan Mikhailidis, D.P., 2013. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? *Public Health*, **127**: 435–441.
- Katzung, B.G., Masters, S.B., dan Trevor, A.J., 2009. *Basic and Clinical Pharmacology, 11th Edition*. McGraw Hill Professional.
- Kauffman, A.B., Olson, K.L., Youngblood, M.L., Zadvorny, E.B., Delate, T., dan Merenich, J.A., 2010. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. *Journal of Clinical Lipidology*, **4**: 173–180.
- Kim, M.C., Ahn, Y., Jang, S.Y., Cho, K.H., Hwang, S.H., Lee, M.G., dkk., 2011. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. *The Korean Journal of Internal Medicine*, **26**: 294–303.
- Kowalak, J., Welsh, W., dan Mayer, 2003. *Buku Ajar Patofisiologi*. EGC Penerbit Buku Kedokteran, Jakarta.
- Lailatushifah, S.N., 2014. 'Kepatuhan Pasien yang Menderita Penyakit Kronis dalam Mengonsumsi Obat Harian', . URL: <http://fpsi.mercubuana-yogya.ac.id/wp-content/uploads/2012/06/Noor-Kepatuhan...pdf> (diakses tanggal 8/6/2016).
- Lewis, S.L., Dirksen, S.R., Heitkemper, M.M., Bucher, L., dan Camera, I., 2010. *Medical-Surgical Nursing: Assessment and Management of Clinical Problems, 8th Edition*, 8th edition. ed. Elsevier Mosby, St. Louis, Mo.
- Lima, J.A.C., Desai, M.Y., Steen, H., Warren, W.P., Gautam, S., dan Lai, S., 2004. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. *Circulation*, **110**: 2336–2341.
- Mahamuni, S.P., Khose, R.D., Menaa, F., dan Badole, S.L., 2012. Therapeutic approaches to drug targets in hyperlipidemia. *BioMedicine*, **2**: 137–146.
- Mangoni, A.A. dan Jackson, S.H.D., 2004. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *British Journal of Clinical Pharmacology*, **57**: 6–14.
- Marrett, E., Zhao, C., Zhang, N.J., Zhang, Q., Ramey, D., Tomassini, J., dkk., 2014. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. *Vascular Health and Risk Management*, **10**: 237–246.

- Milionis, H.J., Rizos, E., dan Mikhailidis, D.P., 2001. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. *Angiology*, **52**: 575–587.
- Morrone, D., Weintraub, W.S., Toth, P.P., Hanson, M.E., Lowe, R.S., Lin, J., dkk., 2012. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. *Atherosclerosis*, **223**: 251–261.
- Munawar, M., Hartono, B., dan Rifqi, S., 2013. LDL Cholesterol Goal Attainment in Hypercholesterolemia: CEPHEUS Indonesian Survey **29**: 7–81.
- Murray, C. dan Lopez, A., 1997. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *The Lancet*, .
- NIH, 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, **106**: 3143–3421.
- Olsson, A.G., Lindahl, C., Holme, I., Fayyad, R., Faergeman, O., Kastelein, J.J., dkk., 2011. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. *European Journal of Cardiovascular Prevention & Rehabilitation*, **18**: 262–269.
- Page, R.L. dan Nappi, J.M., 2013. Acut Coronary Syndrome, dalam: *Koda-Kimble and Young's Applied Therapeutics The Clinical Use of Drug.* Phialadelphia, hal. 408.
- Pamela, 2008. 'Hubungan Antara Kadar LDL Darah pada Stroke Iskemik Fase Akut dengan Lama Perawatan Pasien Pulang Hidup dan Pulang Meninggal', . Fakultas Kedokteran Universitas Diponegoro, Semarang.
- Price, S.. dan Wilson, L., 2006. *Patofisiologi Konsep Klinik Proses Penyakit*, VI. ed. Penerbit Buku Kedokteran, EGC, Jakarta.
- Purnomo, S., 2007. *Dasar Molekular Penyakit Aterosklerosis : Kapita Selektta Ilmu Kedokteran Molekuler*, Cetakan II. ed. Sagung Seto, Jakarta.
- Randall, O.S., Segerson, N., dan Romaine, D., 2010. *The Encyclopedia of the Heart and Heart Disease*, 2 nd. ed. Fact on File, New York.
- Rokhaeni, H., Purnamasari, E., dan Rahayoe, A.U., 2001. *Buku Ajar Keperawatan Kardiovaskuler*, Pertama. ed. Pusat Harapan Kita, Jakarta.

- Rutishauser, J., 2006. The role of statins in clinical medicine--LDL--cholesterol lowering and beyond. *Swiss Medical Weekly*, **136**: 41–49.
- Sargowo, H.D., 1997. Peran Radikal Bebas dalam Patogenesis Aterosklerosis. *Kardiologi*, **XXII.3**: 169–175.
- Sastroasmoro, S. dan Ismael, S., 2011. *Dasar-Dasar Metodologi Penelitian Klinis*, 4th ed. ed. Sagung Seto, Jakarta.
- Schwartz, Olsson AG, Ezekowitz MD, dan et al, 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The miracl study: a randomized controlled trial. *JAMA*, **285**: 1711–1718.
- Silbernagl, S. dan Lang, F., 2006. *Teks & Atlas Berwarna Patofisiologi Color Atlas of Phathophysiology*. Penerbit Buku Kedokteran, EGC, Jakarta.
- Soeharto, I., 2004. *Penyakit Jantung Koroner Dan Serangan Jantung*. Gramedia Pustaka Utama, Jakarta.
- Sorrentino, M.J., 2012. An Update on Statin Alternatives and Adjuncts. *Clinical Lipidology*, **7**: 721–30.
- Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., dkk., 2014. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, **63**: 270–7.
- Stramba-Badiale, M., Fox, K.M., Priori, S.G., Collins, P., Daly, C., Graham, I., dkk., 2006. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. *European Heart Journal*, **27**: 994–1005.
- Vasa, M., Fichtlscherer, S., Adler, K., Aicher, A., Martin, H., Zeiher, A.M., dkk., 2001. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circulation*, **103**: 2885–2890.
- Vonbank, A., Saely, C.H., Rein, P., Sturn, D., dan Drexel, H., 2013. Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients. *Swiss Medical Weekly*, **143**: w13828.
- Wiklund, O., Pirazzi, C., dan Romeo, S., 2013. Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. *Current Cardiology Reports*, **15**: 1–10.

Zhang, R., Zhao, L., Liang, L., Xie, G., dan Wu, Y., 2012. Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy. *Lipids in Health and Disease*, **11**: 11–59.